With more than 16 years’ experience in the therapeutic nucleic acid market Axolabs is a leading Contract Research, Development and Manufacturing Organisation, focused on discovery and pre-clinical research solutions with focus on oligonucleotides and other nucleic acids including consultancy, oligo manufacturing, analytics, bioanalytics (GLP/GCP), lead molecule identification, in vitro and in vivo biology and pharmacology.
The company was founded in 2000 as Ribopharma, a spin-out from the University of Bayreuth, as the world’s first RNAi therapeutics company. It subsequently became part of Alnylam and then Roche and was the subject of a management buy-out in late 2011, then focusing on contract research. Since April 2017 Axolabs belongs to the LGC group.